BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

Allogene Therapeutics (ALLO)Allogene TherapeuticsClinical readout

Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT / 5:00 p.m. ET ALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy Data from the Phase 1 RESOLUTION Study Scheduled for November 9, 2026 at 6:00

Related news

ALLOAllogene Therapeutics2026-07-15 12:30 EST

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLOAllogene Therapeutics2026-04-21 12:30 EST

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

LEGNLegend Biotech Corporation2026-06-02 13:30 EST

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

ALLOAllogene Therapeutics2026-11-05 21:02 EST

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-11-03 13:00 EST

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

ALLOAllogene Therapeutics2026-10-29 12:30 EST

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

ALLOAllogene Therapeutics2026-10-26 12:30 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-09-02 12:30 EST

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

Stock data

Close
1.09 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States